Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Bi-Carzem SR 90mg capsules
0206020C0BRABAT
|
Bi-Carzem | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Bi-Carzem XL 240mg capsules
0206020C0BRADAW
|
Bi-Carzem | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Bi-Carzem XL 300mg capsules
0206020C0BRAEAE
|
Bi-Carzem | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Biofactor Streptokinase 1.5million unit inf vials
0210020L0BDACAE
|
Biofactor Streptokinase | Streptokinase | Cardiovascular System | No data available |
|
Biofactor Streptokinase 250,000unit inf vials
0210020L0BDAAAB
|
Biofactor Streptokinase | Streptokinase | Cardiovascular System | No data available |
|
Biofactor Streptokinase 750,000unit inf vials
0210020L0BDABAD
|
Biofactor Streptokinase | Streptokinase | Cardiovascular System | No data available |
|
Biovea Policosanol 10mg capsules
0212000AGBBAAAA
|
Biovea Policosanol | Policosanol | Cardiovascular System | No data available |
|
Bipranix 10mg tablets
0204000H0BGABAB
|
Bipranix | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bipranix 5mg tablets
0204000H0BGAAAA
|
Bipranix | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bisoprolol 1.667mg/5ml oral liquid
0204000H0AAASAS
|
Bisoprolol fumarate | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bisoprolol 10mg / Aspirin 100mg capsules
0204000ACAAACAC
|
Bisoprolol fumarate/aspirin | Bisoprolol fumarate/aspirin | Cardiovascular System | No data available |
|
Bisoprolol 10mg / Aspirin 75mg capsules
0204000ACAAABAB
|
Bisoprolol fumarate/aspirin | Bisoprolol fumarate/aspirin | Cardiovascular System | No data available |
|
Bisoprolol 10mg / Hydrochlorothiazide 6.25mg tablets
020400090AAAAAA
|
Generic tablet | Bisoprolol fumarate with diuretic | Cardiovascular System | No data available |
|
Bisoprolol 1mg/5ml oral liquid
0204000H0AAAEAE
|
Bisoprolol fumarate | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bisoprolol 1mg/ml oral solution sugar free
0204000H0AABKBK
|
Bisoprolol fumarate | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bisoprolol 500micrograms/ml oral solution sugar free
0204000H0AABLBL
|
Bisoprolol fumarate | Bisoprolol fumarate | Cardiovascular System | No data available |
|
Bisoprolol 5mg / Aspirin 100mg capsules
0204000ACAAADAD
|
Bisoprolol fumarate/aspirin | Bisoprolol fumarate/aspirin | Cardiovascular System | No data available |
|
Bisoprolol 5mg / Aspirin 75mg capsules
0204000ACAAAAAA
|
Bisoprolol fumarate/aspirin | Bisoprolol fumarate/aspirin | Cardiovascular System | No data available |
|
Boots Aspirin 75mg gastro-resistant tablets
0209000A0BPAAAK
|
Boots Aspirin | Aspirin | Cardiovascular System | No data available |
|
Bosentan 62.5mg tablets
0205010U0AAAAAA
|
Bosentan | Bosentan | Cardiovascular System | No data available |
|
Bretylate 100mg/2ml solution for injection ampoules
0203020E0BBAAAA
|
Bretylate | Bretylium tosilate | Cardiovascular System | No data available |
|
Bretylate 500mg/10ml solution for injection ampoules
0203020E0BBABAC
|
Bretylate | Bretylium tosilate | Cardiovascular System | No data available |
|
Bretylium tosilate 100mg/2ml solution for injection ampoules
0203020E0AAAAAA
|
Bretylium tosilate | Bretylium tosilate | Cardiovascular System | No data available |
|
Bretylium tosilate 500mg/10ml inj ampoules
0203020E0AAACAC
|
Bretylium tosilate | Bretylium tosilate | Cardiovascular System | No data available |
|
Bretylium tosilate 500mg/10ml inj Minijet pfs
0203020E0BCAAAB
|
Minjet bretylium tosilate | Bretylium tosilate | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.